Impact of Pioglitazone, Metformin and the Combination of Both on Cardiovascular Risk in Insulin-Treated Patients With Type 2 Diabetes - The PIOcomb Study.

Trial Profile

Impact of Pioglitazone, Metformin and the Combination of Both on Cardiovascular Risk in Insulin-Treated Patients With Type 2 Diabetes - The PIOcomb Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2013

At a glance

  • Drugs Metformin (Primary) ; Pioglitazone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacodynamics
  • Acronyms PIOcomb
  • Sponsors Takeda Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Apr 2012 Planned number of patients changed from 132 to 300 as reported by EudraCT.
    • 28 Apr 2012 Additional trial location (Austria) identified as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top